ArticleFrontiers in immunology2026
A single-dose mRNA vaccine induces potent and long-lasting humoral and cellular immunity against the varicella-zoster virus in a murine model.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Herpes zoster is an infectious disease caused by the varicella-zoster virus (VZV). In adults, the reactivation of VZV can lead to severe neuralgia and skin rashes. Although the licensed vaccines are available, their associated adverse reactions and the shortage of required adjuvants necessitate the development of novel VZV vaccines. Methods: We developed a novel VZV mRNA vaccine candidate (named as KH014) containing sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in an ionizable lipid nanoparticle. Its immunogenicity was evaluated in BALB/c mice receiving single-dose, two-dose, or heterologous prime-boost regimens in comparison with the licensed adjuvanted subunit vaccine Shingrix®. Humoral responses were assessed by ELISA and microneutralization assays; cellular immunity was characterized by ELISpot, intracellular cytokine staining, and memory T-cell phenotyping via flow cytometry. Results: In mice, immunization with either a single-dose or two-dose of KH014 elicited superior VZV-specific humoral and cellular immune responses compared to the licensed vaccine Shingrix Conclusion: The KH014 mRNA vaccine candidate induces robust and durable humoral and cellular immunity against VZV in mice, with a single dose sufficient to elicit T-cell responses superior to those of two-dose Shingrix
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.